Breast Diseases  >>  epirubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epirubicin / Generic mfg.
NCT00140075: Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Completed
3
606
US
Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin, ellence,, Epirubicin with a Taxane
Pfizer
Adenocarcinoma
08/06
08/06
PREPARE, NCT00544232: Preoperative Epirubicin Paclitaxel Aranesp Study

Completed
3
720
Europe
Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa, Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
German Breast Group, Pharmacia, Amgen, Bristol-Myers Squibb
Breast Cancer
09/06
09/06
NCT00309556 / 2004-002030-19: Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Checkmark Epirubicin & docetaxel with or without capecitabine as neoadj treatment for early BC
Dec 2013 - Dec 2013:  Epirubicin & docetaxel with or without capecitabine as neoadj treatment for early BC
Completed
3
536
Europe
Epirubicin, Docetaxel, Taxotere, Capecitabine, Xeloda, Trastuzumab, Herceptin
Austrian Breast & Colorectal Cancer Study Group, Amgen, Ebewe Pharma GmbH, Hoffmann-La Roche, Sanofi
Breast Cancer
11/09
11/11
BO22227, NCT00950300 / 2008-007326-19: A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Checkmark P3 data - ESMO
Sep 2012 - Sep 2012: P3 data - ESMO
Checkmark P3 data - ESMO
Sep 2012 - Sep 2012: P3 data - ESMO
Checkmark P3 data - ESMO
More
Completed
3
596
Canada, Europe, RoW
5-Fluorouracil, Cyclophosphamide, Docetaxel, Epirubicin, Herceptin IV [trastuzumab], Herceptin SC [trastuzumab]
Hoffmann-La Roche
Breast Cancer
07/11
01/17
READ, NCT00689156 / 2007-003126-15: Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer

Completed
3
2015
Europe
Epirubicin, cyclophosphamide and docetaxel, Ellence, Taxotere, docetaxel, cyclophosphamide
Danish Breast Cancer Cooperative Group, Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning, Sanofi, Dako
Breast Neoplasms
01/13
01/13
NCT01611051: A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Completed
3
330
RoW
Drug: Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg, rhG-CSF 5ug/kg/day
Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Neutropenia, Febrile Neutropenia
01/13
 
GeparOcto, NCT02125344 / 2014-000619-14: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer

Completed
3
961
Europe
non-pegylated liposomal doxorubicin, Myocet, Carboplatin, Carbomedac, Paclitaxel, var., Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Ferric carboxymaltose, Ferinject
German Breast Group, Amgen, Roche Pharma AG, Teva Pharmaceuticals USA, Vifor Pharma
Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer
11/16
01/17
NCT01433562: Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

Completed
2/3
40
RoW
DLBS1425, Placebo DLBS1425
Dexa Medica Group
Breast Cancer
11/12
11/12

Download Options